메뉴 건너뛰기




Volumn 99, Issue 6, 2008, Pages 1001-1007

Pathophysiological considerations to thrombophilia in the treatment of multiple myeloma with thalidomide and derivates

Author keywords

Lenalidomide; Multiple myeloma; Prophylaxis; Thalidomide; Thrombosis

Indexed keywords

ACETYLSALICYLIC ACID; ANTHRACYCLINE; DEXAMETHASONE; DOXORUBICIN; ENOXAPARIN; ERYTHROPOIETIN; IMMUNOMODULATING AGENT; LENALIDOMIDE; LOW MOLECULAR WEIGHT HEPARIN; MELPHALAN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PARAPROTEIN; THALIDOMIDE; THALIDOMIDE DERIVATIVE; THROMBIN; VON WILLEBRAND FACTOR; WARFARIN;

EID: 44949239424     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH08-01-0009     Document Type: Review
Times cited : (15)

References (84)
  • 2
    • 0033083962 scopus 로고    scopus 로고
    • Expression of vascular endothelial growth factor and its receptors in hematopoietic malignancies
    • Bellamy WT, Richter L, Frutiger Y, et al. Expression of vascular endothelial growth factor and its receptors in hematopoietic malignancies. Cancer Res 1999; 59: 728-733.
    • (1999) Cancer Res , vol.59 , pp. 728-733
    • Bellamy, W.T.1    Richter, L.2    Frutiger, Y.3
  • 3
    • 0032748385 scopus 로고    scopus 로고
    • Antitumor activity of thalidomide in refractory multiple myeloma
    • Singhal S, Mehta J, Desikan R, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999; 341: 1565-1571.
    • (1999) N Engl J Med , vol.341 , pp. 1565-1571
    • Singhal, S.1    Mehta, J.2    Desikan, R.3
  • 4
    • 0035674462 scopus 로고    scopus 로고
    • Angiogenesis in hematologic malignancies
    • Moehler TM, Neben K, Ho AD, et al. Angiogenesis in hematologic malignancies. Ann Hematol 2001; 80: 695-705.
    • (2001) Ann Hematol , vol.80 , pp. 695-705
    • Moehler, T.M.1    Neben, K.2    Ho, A.D.3
  • 5
    • 0035672117 scopus 로고    scopus 로고
    • Response to thalidomide in progressive multiple myeloma is not mediated by inhibition of angiogenic cytokine secretion
    • Neben K, Moehler T, Kraemer A, et al. Response to thalidomide in progressive multiple myeloma is not mediated by inhibition of angiogenic cytokine secretion. Br J Haematol 2001; 115: 605-608.
    • (2001) Br J Haematol , vol.115 , pp. 605-608
    • Neben, K.1    Moehler, T.2    Kraemer, A.3
  • 6
    • 0036381106 scopus 로고    scopus 로고
    • Thalidomide and its analogues have distinct and opposing effects on TNF-alpha and TNFR2 during co-stimulation of both CD4(+) and CD8(+) T cells
    • Marriott JB, Clarke IA, Dredge K, et al. Thalidomide and its analogues have distinct and opposing effects on TNF-alpha and TNFR2 during co-stimulation of both CD4(+) and CD8(+) T cells. Clin Exp Immunol 2002; 130: 75-84.
    • (2002) Clin Exp Immunol , vol.130 , pp. 75-84
    • Marriott, J.B.1    Clarke, I.A.2    Dredge, K.3
  • 7
    • 27644591608 scopus 로고    scopus 로고
    • Properties of thalidomide and its analogues: Implications for anticancer therapy
    • Teo SK. Properties of thalidomide and its analogues: implications for anticancer therapy. Aaps J 2005; 7: E14-19.
    • Aaps , vol.J 2005 , Issue.7
    • Teo, S.K.1
  • 8
    • 8844219644 scopus 로고    scopus 로고
    • PI3-K/AKT/FKHR and MAPK signaling cascades are redundantly stimulated by a variety of cytokines and contribute independently to proliferation and survival of multiple myeloma cells
    • Lentzsch S, Chatterjee M, Gries M, et al. PI3-K/AKT/FKHR and MAPK signaling cascades are redundantly stimulated by a variety of cytokines and contribute independently to proliferation and survival of multiple myeloma cells. Leukemia 2004; 18: 1883-1890.
    • (2004) Leukemia , vol.18 , pp. 1883-1890
    • Lentzsch, S.1    Chatterjee, M.2    Gries, M.3
  • 9
    • 33846665934 scopus 로고    scopus 로고
    • Lenalidomide and CC-4047 inhibit the proliferation of malignant B cells while expanding normal CD34+ progenitor cells
    • Verhelle D, Corral LG, Wong K, et al. Lenalidomide and CC-4047 inhibit the proliferation of malignant B cells while expanding normal CD34+ progenitor cells. Cancer Res 2007; 67: 746-755.
    • (2007) Cancer Res , vol.67 , pp. 746-755
    • Verhelle, D.1    Corral, L.G.2    Wong, K.3
  • 10
    • 0034331194 scopus 로고    scopus 로고
    • Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy
    • Hideshima T, Chauhan D, Shima Y, et al. Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood 2000; 96: 2943-2950.
    • (2000) Blood , vol.96 , pp. 2943-2950
    • Hideshima, T.1    Chauhan, D.2    Shima, Y.3
  • 11
    • 33646494190 scopus 로고    scopus 로고
    • Lenalidomide and venous thrombosis in multiple myeloma
    • Knight R, DeLap RJ, Zeldis JB. Lenalidomide and venous thrombosis in multiple myeloma. N Engl J Med 2006; 354: 2079-2080.
    • (2006) N Engl J Med , vol.354 , pp. 2079-2080
    • Knight, R.1    DeLap, R.J.2    Zeldis, J.B.3
  • 12
    • 28844490092 scopus 로고    scopus 로고
    • Management of the relapsed/refractory myeloma patient: Strategies incorporating lenalidomide
    • Richardson P. Management of the relapsed/refractory myeloma patient: strategies incorporating lenalidomide. Semin Hematol 2005; 42 (4 Suppl 4): S9-15.
    • (2005) Semin Hematol , vol.42 , Issue.4 SUPPL. 4
    • Richardson, P.1
  • 13
    • 33745291997 scopus 로고    scopus 로고
    • Thromboembolism risk reduction in multiple myeloma patients treated with immunomodulatory drug combinations
    • Hussein MA. Thromboembolism risk reduction in multiple myeloma patients treated with immunomodulatory drug combinations. Thromb Haemost 2006; 95: 924-930.
    • (2006) Thromb Haemost , vol.95 , pp. 924-930
    • Hussein, M.A.1
  • 14
    • 28844496656 scopus 로고    scopus 로고
    • Lenalidomide: Patient management strategies
    • Hussein MA. Lenalidomide: patient management strategies. Semin Hematol 2005; 42 (4 Suppl 4): S22-25.
    • (2005) Semin Hematol , vol.42 , Issue.4 SUPPL. 4
    • Hussein, M.A.1
  • 15
    • 0035210668 scopus 로고    scopus 로고
    • Thalidomide in the management of multiple myeloma
    • Barlogie B, Tricot G, Anaissie E. Thalidomide in the management of multiple myeloma. Semin Oncol 2001; 28: 577-582.
    • (2001) Semin Oncol , vol.28 , pp. 577-582
    • Barlogie, B.1    Tricot, G.2    Anaissie, E.3
  • 16
    • 33644898842 scopus 로고    scopus 로고
    • A systematic review of phase-II trials of thalidomide monotherapy in patients with relapsed or refractory multiple myeloma
    • Glasmacher A, Hahn C, Hoffmann F, Naumann R, Goldschmidt H, von Lilienfeld-Toal M, et al. A systematic review of phase-II trials of thalidomide monotherapy in patients with relapsed or refractory multiple myeloma. Br J Haematol 2006; 132: 584-593.
    • (2006) Br J Haematol , vol.132 , pp. 584-593
    • Glasmacher, A.1    Hahn, C.2    Hoffmann, F.3    Naumann, R.4    Goldschmidt, H.5    von Lilienfeld-Toal, M.6
  • 17
    • 0037716629 scopus 로고    scopus 로고
    • Management of multiple myeloma: A systematic review and critical appraisal of published studies
    • Kumar A, Loughran T, Alsina M, et al. Management of multiple myeloma: a systematic review and critical appraisal of published studies. Lancet Oncol 2003; 4: 293-304.
    • (2003) Lancet Oncol , vol.4 , pp. 293-304
    • Kumar, A.1    Loughran, T.2    Alsina, M.3
  • 18
    • 0037216068 scopus 로고    scopus 로고
    • Response rate, durability of response, and survival after thalidomide therapy for relapsed multiple myeloma
    • Kumar S, Gertz MA, Dispenzieri A, et al. Response rate, durability of response, and survival after thalidomide therapy for relapsed multiple myeloma. Mayo Clin Proc 2003; 78: 34-39.
    • (2003) Mayo Clin Proc , vol.78 , pp. 34-39
    • Kumar, S.1    Gertz, M.A.2    Dispenzieri, A.3
  • 19
    • 0036196843 scopus 로고    scopus 로고
    • Thalidomide in multiple myeloma: State of art
    • Tosi P, Cavo M. Thalidomide in multiple myeloma: state of art. Haematologica 2002; 87: 233-234.
    • (2002) Haematologica , vol.87 , pp. 233-234
    • Tosi, P.1    Cavo, M.2
  • 20
    • 19944368366 scopus 로고    scopus 로고
    • Prevention of venous thromboembolism with low molecular-weight heparin in patients with multiple myeloma treated with thalidomide and chemotherapy
    • Minnema MC, Breitkreutz I, Auwerda JJ, et al. Prevention of venous thromboembolism with low molecular-weight heparin in patients with multiple myeloma treated with thalidomide and chemotherapy. Leukemia 2004; 18: 2044-2046.
    • (2004) Leukemia , vol.18 , pp. 2044-2046
    • Minnema, M.C.1    Breitkreutz, I.2    Auwerda, J.J.3
  • 21
    • 4544332965 scopus 로고    scopus 로고
    • Deep vein thrombosis in patients with multiple myeloma treated with thalidomide and chemotherapy: Effects of prophylactic and therapeutic anticoagulation
    • Zangari M, Barlogie B, Anaissie E, et al. Deep vein thrombosis in patients with multiple myeloma treated with thalidomide and chemotherapy: effects of prophylactic and therapeutic anticoagulation. Br J Haematol 2004; 126: 715-721.
    • (2004) Br J Haematol , vol.126 , pp. 715-721
    • Zangari, M.1    Barlogie, B.2    Anaissie, E.3
  • 22
    • 1842687760 scopus 로고    scopus 로고
    • Thrombotic complications associated with thalidomide in multiple myeloma: An old problem with new questions and quandaries in decision-making
    • Potenza L, Luppi M, Morselli M, et al. Thrombotic complications associated with thalidomide in multiple myeloma: an old problem with new questions and quandaries in decision-making. Thromb Haemost 2004; 91: 834-836.
    • (2004) Thromb Haemost , vol.91 , pp. 834-836
    • Potenza, L.1    Luppi, M.2    Morselli, M.3
  • 24
    • 0037105601 scopus 로고    scopus 로고
    • Deep-vein thrombosis in patients with multiple myeloma receiving first-line thalidomide-dexamethasone therapy
    • Cavo M, Zamagni E, Cellini C, et al. Deep-vein thrombosis in patients with multiple myeloma receiving first-line thalidomide-dexamethasone therapy. Blood 2002; 100: 2272-2273.
    • (2002) Blood , vol.100 , pp. 2272-2273
    • Cavo, M.1    Zamagni, E.2    Cellini, C.3
  • 25
    • 0347383743 scopus 로고    scopus 로고
    • Thalidomide in newly diagnosed multiple myeloma and overview of experience in smoldering/ indolent disease
    • Rajkumar SV. Thalidomide in newly diagnosed multiple myeloma and overview of experience in smoldering/ indolent disease. Semin Hematol 2003; 40 (4 Suppl 4): 17-22.
    • (2003) Semin Hematol , vol.40 , Issue.4 SUPPL. 4 , pp. 17-22
    • Rajkumar, S.V.1
  • 26
    • 0037396605 scopus 로고    scopus 로고
    • Thalidomide as initial therapy for early-stage myeloma
    • Rajkumar SV, Gertz MA, Lacy MQ, et al. Thalidomide as initial therapy for early-stage myeloma. Leukemia 2003; 17: 775-779.
    • (2003) Leukemia , vol.17 , pp. 775-779
    • Rajkumar, S.V.1    Gertz, M.A.2    Lacy, M.Q.3
  • 27
    • 0037393945 scopus 로고    scopus 로고
    • Thromboembolic events in patients with myelodysplastic syndrome receiving thalidomide in combination with darbepoietin-alpha
    • Steurer M, Sudmeier I, Stauder R, et al. Thromboembolic events in patients with myelodysplastic syndrome receiving thalidomide in combination with darbepoietin-alpha. Br J Haematol 2003; 121: 101-103.
    • (2003) Br J Haematol , vol.121 , pp. 101-103
    • Steurer, M.1    Sudmeier, I.2    Stauder, R.3
  • 28
    • 13244271291 scopus 로고    scopus 로고
    • Thalidomide in front line treatment in multiple myeloma: Serious risk of venous thromboembolism and evidence for thromboprophylaxis
    • Rus C, Bazzan M, Palumbo A, et al. Thalidomide in front line treatment in multiple myeloma: serious risk of venous thromboembolism and evidence for thromboprophylaxis. J Thromb Haemost 2004; 2: 2063-2065.
    • (2004) J Thromb Haemost , vol.2 , pp. 2063-2065
    • Rus, C.1    Bazzan, M.2    Palumbo, A.3
  • 29
    • 33748700214 scopus 로고    scopus 로고
    • Acquired activated protein C resistance and thrombosis in multiple myeloma patients
    • Jimenez-Zepeda VH, Dominguez-Martinez VJ. Acquired activated protein C resistance and thrombosis in multiple myeloma patients. Thromb J 2006; 4: 11.
    • (2006) Thromb J , vol.4 , pp. 11
    • Jimenez-Zepeda, V.H.1    Dominguez-Martinez, V.J.2
  • 30
    • 33746054911 scopus 로고    scopus 로고
    • Acquired resistance to activated protein C (aAPCR) in multiple myeloma is a transitory abnormality associated with an increased risk of venous thromboembolism
    • Elice F, Fink L, Tricot G, et al. Acquired resistance to activated protein C (aAPCR) in multiple myeloma is a transitory abnormality associated with an increased risk of venous thromboembolism. Br J Haematol 2006; 134: 399-405.
    • (2006) Br J Haematol , vol.134 , pp. 399-405
    • Elice, F.1    Fink, L.2    Tricot, G.3
  • 31
    • 0026708195 scopus 로고
    • C-reactive protein and beta-2 microglobulin produce a simple and powerful myeloma staging system
    • Bataille R, Boccadoro M, Klein B, et al. C-reactive protein and beta-2 microglobulin produce a simple and powerful myeloma staging system. Blood 1992; 80: 733-737.
    • (1992) Blood , vol.80 , pp. 733-737
    • Bataille, R.1    Boccadoro, M.2    Klein, B.3
  • 32
    • 0031257715 scopus 로고    scopus 로고
    • Serum soluble IL-6 receptor concentrations correlate with stages of multiple myeloma defined by serum beta 2-microglobulin and C-reactive protein
    • Kyriakou D, Papadaki H, Eliopoulos AG, et al. Serum soluble IL-6 receptor concentrations correlate with stages of multiple myeloma defined by serum beta 2-microglobulin and C-reactive protein. Int J Hematol 1997; 66: 367-371.
    • (1997) Int J Hematol , vol.66 , pp. 367-371
    • Kyriakou, D.1    Papadaki, H.2    Eliopoulos, A.G.3
  • 33
    • 0026560724 scopus 로고
    • Radioimmunoassay for the measurement of serum IL-6 and its correlation with tumour cell mass parameters in multiple myeloma
    • Solary E, Guiguet M, Zeller V, et al. Radioimmunoassay for the measurement of serum IL-6 and its correlation with tumour cell mass parameters in multiple myeloma. Am J Hematol 1992; 39: 163-171.
    • (1992) Am J Hematol , vol.39 , pp. 163-171
    • Solary, E.1    Guiguet, M.2    Zeller, V.3
  • 34
    • 33748700214 scopus 로고    scopus 로고
    • Acquired activated protein C resistance and thrombosis in multiple myeloma patients
    • Hugo JZ, Jeanet DM. Acquired activated protein C resistance and thrombosis in multiple myeloma patients. Thromb J 2006; 4: 11.
    • (2006) Thromb J , vol.4 , pp. 11
    • Hugo, J.Z.1    Jeanet, D.M.2
  • 35
    • 0023484707 scopus 로고
    • A fatal thrombotic disorder associated with an acquired inhibitor of protein C
    • Mitchell CA, Rowell JA, Hau L, et al. A fatal thrombotic disorder associated with an acquired inhibitor of protein C. N Engl J Med 1987; 317: 1638-1642.
    • (1987) N Engl J Med , vol.317 , pp. 1638-1642
    • Mitchell, C.A.1    Rowell, J.A.2    Hau, L.3
  • 36
    • 0033179471 scopus 로고    scopus 로고
    • Extensive venous and arterial thrombosis associated with an inhibitor to activated protein C
    • Zivelin A, Gitel S, Griffin JH, et al. Extensive venous and arterial thrombosis associated with an inhibitor to activated protein C. Blood 1999; 94: 895-901.
    • (1999) Blood , vol.94 , pp. 895-901
    • Zivelin, A.1    Gitel, S.2    Griffin, J.H.3
  • 38
    • 0028300171 scopus 로고
    • Antithrombin and its inherited deficiencies
    • Perry DJ. Antithrombin and its inherited deficiencies. Blood Rev 1994; 8: 37-55.
    • (1994) Blood Rev , vol.8 , pp. 37-55
    • Perry, D.J.1
  • 39
    • 4444308010 scopus 로고    scopus 로고
    • Modification of thrombomodulin plasma levels in refractory myeloma patients during treatment with thalidomide and dexamethasone
    • Corso A, Lorenzi A, Terulla V, et al. Modification of thrombomodulin plasma levels in refractory myeloma patients during treatment with thalidomide and dexamethasone. Ann Hematol 2004; 83: 588-591.
    • (2004) Ann Hematol , vol.83 , pp. 588-591
    • Corso, A.1    Lorenzi, A.2    Terulla, V.3
  • 40
    • 15744401626 scopus 로고    scopus 로고
    • Activation of the coagulation system in cancerogenesis and metastasation
    • Xie WZ, Leibl M, Clark MR, et al. Activation of the coagulation system in cancerogenesis and metastasation. Biomed Pharmacother 2005; 59: 70-75.
    • (2005) Biomed Pharmacother , vol.59 , pp. 70-75
    • Xie, W.Z.1    Leibl, M.2    Clark, M.R.3
  • 41
    • 0036025255 scopus 로고    scopus 로고
    • Increased endothelial thrombomodulin (TM) expression in pregnancies complicated by IUGR
    • Wienhard J, Bielska B, Munstedt K, et al. Increased endothelial thrombomodulin (TM) expression in pregnancies complicated by IUGR. J Perinat Med 2002; 30: 322-328.
    • (2002) J Perinat Med , vol.30 , pp. 322-328
    • Wienhard, J.1    Bielska, B.2    Munstedt, K.3
  • 42
    • 0141819138 scopus 로고    scopus 로고
    • The protein C pathway
    • Esmon CT. The protein C pathway. Chest 2003; 124 (3 Suppl): 26S-32S.
    • (2003) Chest , vol.124 , Issue.3 SUPPL.
    • Esmon, C.T.1
  • 43
    • 0024558370 scopus 로고
    • The roles of protein C and thrombomodulin in the regulation of blood coagulation
    • Esmon CT. The roles of protein C and thrombomodulin in the regulation of blood coagulation. J Biol Chem 1989; 264: 4743-4746.
    • (1989) J Biol Chem , vol.264 , pp. 4743-4746
    • Esmon, C.T.1
  • 44
    • 0025896578 scopus 로고
    • Soluble thrombomodulin antigen in conditioned medium is increased by damage of endothelial cells
    • Ishii H, Uchiyama H, Kazama M. Soluble thrombomodulin antigen in conditioned medium is increased by damage of endothelial cells. Thromb Haemost 1991; 65: 618-623.
    • (1991) Thromb Haemost , vol.65 , pp. 618-623
    • Ishii, H.1    Uchiyama, H.2    Kazama, M.3
  • 45
    • 28344436780 scopus 로고    scopus 로고
    • Protease-activated receptors in hemostasis, thrombosis and vascular biology
    • Coughlin SR. Protease-activated receptors in hemostasis, thrombosis and vascular biology. J Thromb Haemost 2005; 3: 1800-1814.
    • (2005) J Thromb Haemost , vol.3 , pp. 1800-1814
    • Coughlin, S.R.1
  • 46
    • 2142651737 scopus 로고    scopus 로고
    • Role of protease-activated receptors in the vascular system
    • Hirano K, Kanaide H. Role of protease-activated receptors in the vascular system. J Atheroscler Thromb 2003; 10: 211-225.
    • (2003) J Atheroscler Thromb , vol.10 , pp. 211-225
    • Hirano, K.1    Kanaide, H.2
  • 47
    • 0042474500 scopus 로고    scopus 로고
    • The role of the tissue factor-thrombin pathway in cardiac ischemia-reperfusion injury
    • Mackman N. The role of the tissue factor-thrombin pathway in cardiac ischemia-reperfusion injury. Semin Vasc Med 2003; 3: 193-198.
    • (2003) Semin Vasc Med , vol.3 , pp. 193-198
    • Mackman, N.1
  • 48
    • 0030868767 scopus 로고    scopus 로고
    • Release of the thrombin receptor (PAR-1) N-terminus from the surface of human platelets activated by thrombin
    • Ramachandran R, Klufas AS, Molino M, et al. Release of the thrombin receptor (PAR-1) N-terminus from the surface of human platelets activated by thrombin. Thromb Haemost 1997; 78: 1119-1124.
    • (1997) Thromb Haemost , vol.78 , pp. 1119-1124
    • Ramachandran, R.1    Klufas, A.S.2    Molino, M.3
  • 49
    • 0033613183 scopus 로고    scopus 로고
    • How the protease thrombin talks to cells
    • Coughlin SR. How the protease thrombin talks to cells. Proc Natl Acad Sci USA 1999; 96: 11023-11027.
    • (1999) Proc Natl Acad Sci USA , vol.96 , pp. 11023-11027
    • Coughlin, S.R.1
  • 50
    • 32844467885 scopus 로고    scopus 로고
    • Commutators of PAR-1 signaling in cancer cell invasion reveal an essential role of the Rho-Rho kinase axis and tumor microenvironment
    • Nguyen QD, De Wever O, Bruyneel E, et al. Commutators of PAR-1 signaling in cancer cell invasion reveal an essential role of the Rho-Rho kinase axis and tumor microenvironment. Oncogene 2005; 24: 8240-8251.
    • (2005) Oncogene , vol.24 , pp. 8240-8251
    • Nguyen, Q.D.1    De Wever, O.2    Bruyneel, E.3
  • 51
    • 0036326388 scopus 로고    scopus 로고
    • Thrombin as a survival factor for cancer cells: Thrombin activation in malignant effusions in vivo and inhibition of idarubicin-induced cell death in vitro
    • Schiller H, Bartscht T, Arlt A, et al. Thrombin as a survival factor for cancer cells: thrombin activation in malignant effusions in vivo and inhibition of idarubicin-induced cell death in vitro. Int J Clin Pharmacol Ther 2002; 40: 329-335.
    • (2002) Int J Clin Pharmacol Ther , vol.40 , pp. 329-335
    • Schiller, H.1    Bartscht, T.2    Arlt, A.3
  • 52
    • 34250617048 scopus 로고    scopus 로고
    • Activated coagulation factors in human malignant effusions and their contribution to cancer cell metastasis and therapy
    • Gieseler F, Luhr I, Kunze T, et al. Activated coagulation factors in human malignant effusions and their contribution to cancer cell metastasis and therapy. Thromb Haemost 2007; 97: 1023-1030.
    • (2007) Thromb Haemost , vol.97 , pp. 1023-1030
    • Gieseler, F.1    Luhr, I.2    Kunze, T.3
  • 53
    • 0034921205 scopus 로고    scopus 로고
    • Protease-activated receptors in vascular biology
    • Coughlin SR. Protease-activated receptors in vascular biology. Thromb Haemost 2001; 86: 298-307.
    • (2001) Thromb Haemost , vol.86 , pp. 298-307
    • Coughlin, S.R.1
  • 54
    • 4644316831 scopus 로고    scopus 로고
    • Thalidomide protects endothelial cells from doxorubicin-induced apoptosis but alters cell morphology
    • Kaushal V, Kaushal GP, Melkaveri SN, et al. Thalidomide protects endothelial cells from doxorubicin-induced apoptosis but alters cell morphology. J Thromb Haemost 2004; 2: 327-334.
    • (2004) J Thromb Haemost , vol.2 , pp. 327-334
    • Kaushal, V.1    Kaushal, G.P.2    Melkaveri, S.N.3
  • 55
    • 0642341991 scopus 로고    scopus 로고
    • Extremely high levels of von Willebrand factor antigen and of procoagulant factor VIII found in multiple myeloma patients are associated with activity status but not with thalidomide treatment
    • Minnema MC, Fijnheer R, De Groot PG, et al. Extremely high levels of von Willebrand factor antigen and of procoagulant factor VIII found in multiple myeloma patients are associated with activity status but not with thalidomide treatment. J Thromb Haemost 2003; 1: 445-449.
    • (2003) J Thromb Haemost , vol.1 , pp. 445-449
    • Minnema, M.C.1    Fijnheer, R.2    De Groot, P.G.3
  • 56
    • 0024418573 scopus 로고
    • Effect of aspirin on platelet-von Willebrand factor surface expression on thrombin and ADP-stimulated platelets
    • Parker RI, Gralnick HR. Effect of aspirin on platelet-von Willebrand factor surface expression on thrombin and ADP-stimulated platelets. Blood 1989; 74: 2016-2021.
    • (1989) Blood , vol.74 , pp. 2016-2021
    • Parker, R.I.1    Gralnick, H.R.2
  • 57
    • 33645509877 scopus 로고    scopus 로고
    • Differential regulation of endothelial exocytosis of P-selectin and von Willebrand factor by protease-activated receptors and cAMP
    • Cleator JH, Zhu WQ, Vaughan DE, et al. Differential regulation of endothelial exocytosis of P-selectin and von Willebrand factor by protease-activated receptors and cAMP. Blood 2006; 107: 2736-2744.
    • (2006) Blood , vol.107 , pp. 2736-2744
    • Cleator, J.H.1    Zhu, W.Q.2    Vaughan, D.E.3
  • 58
    • 0037458275 scopus 로고    scopus 로고
    • Differential actions of PAR2 and PAR1 in stimulating human endothelial cell exocytosis and permeability: The role of Rho-GTPases
    • Klarenbach SW, Chipiuk A, Nelson RC, et al. Differential actions of PAR2 and PAR1 in stimulating human endothelial cell exocytosis and permeability: the role of Rho-GTPases. Circ Res 2003; 92: 272-278.
    • (2003) Circ Res , vol.92 , pp. 272-278
    • Klarenbach, S.W.1    Chipiuk, A.2    Nelson, R.C.3
  • 60
    • 12344282582 scopus 로고    scopus 로고
    • New perspectives on von Willebrand factor functions in hemostasis and thrombosis
    • Mendolicchio GL, Ruggeri ZM. New perspectives on von Willebrand factor functions in hemostasis and thrombosis. Semin Hematol 2005; 42: 5-14.
    • (2005) Semin Hematol , vol.42 , pp. 5-14
    • Mendolicchio, G.L.1    Ruggeri, Z.M.2
  • 61
    • 18144439840 scopus 로고    scopus 로고
    • Effects of various anticoagulant treatments on von Willebrand factor release in unstable angina
    • Montalescot G, Collet JP, Lison L, et al. Effects of various anticoagulant treatments on von Willebrand factor release in unstable angina. J Am Coll Cardiol 2000; 36: 110-114.
    • (2000) J Am Coll Cardiol , vol.36 , pp. 110-114
    • Montalescot, G.1    Collet, J.P.2    Lison, L.3
  • 62
    • 0030338021 scopus 로고    scopus 로고
    • Treatment of hyperviscosity syndrome in the patients with plasma cell dyscrasias
    • Kes P, Pecanic Z, Getaldic B, et al. Treatment of hyperviscosity syndrome in the patients with plasma cell dyscrasias. Acta Med Croatica 1996; 50: 173-177.
    • (1996) Acta Med Croatica , vol.50 , pp. 173-177
    • Kes, P.1    Pecanic, Z.2    Getaldic, B.3
  • 63
    • 0036235777 scopus 로고    scopus 로고
    • Acquired von Willebrand disease - hemostatic management of major orthopedic surgery with high-dose immunoglobulin, desmopressin, and continuous factor concentrate infusion
    • Frank RD, Kunz D, Wirtz DC. Acquired von Willebrand disease - hemostatic management of major orthopedic surgery with high-dose immunoglobulin, desmopressin, and continuous factor concentrate infusion. Am J Hematol 2002; 70: 64-71.
    • (2002) Am J Hematol , vol.70 , pp. 64-71
    • Frank, R.D.1    Kunz, D.2    Wirtz, D.C.3
  • 64
    • 0026496615 scopus 로고
    • Acquired von Willebrand's disease
    • Jakway JL. Acquired von Willebrand's disease. Hematol Oncol Clin North Am 1992; 6: 1409-1419.
    • (1992) Hematol Oncol Clin North Am , vol.6 , pp. 1409-1419
    • Jakway, J.L.1
  • 65
    • 0023268127 scopus 로고
    • Acquired von Willebrand disease due to inhibitor of human myeloma protein specific for von Willebrand factor
    • Mohri H, Noguchi T, Kodama F, et al. Acquired von Willebrand disease due to inhibitor of human myeloma protein specific for von Willebrand factor. Am J Clin Pathol 1987; 87: 663-668.
    • (1987) Am J Clin Pathol , vol.87 , pp. 663-668
    • Mohri, H.1    Noguchi, T.2    Kodama, F.3
  • 66
    • 0022644335 scopus 로고
    • A human myeloma-produced monoclonal protein directed against the active subpopulation of von Willebrand factor
    • Bovill EG, Ershler WB, Golden EA, et al. A human myeloma-produced monoclonal protein directed against the active subpopulation of von Willebrand factor. Am J Clin Pathol 1986; 85: 115-123.
    • (1986) Am J Clin Pathol , vol.85 , pp. 115-123
    • Bovill, E.G.1    Ershler, W.B.2    Golden, E.A.3
  • 67
    • 0015296641 scopus 로고
    • Inhibition of fibrin monomer polymerization by lambda myeloma globulins
    • Coleman M, Vigliano EM, Weksler ME, et al. Inhibition of fibrin monomer polymerization by lambda myeloma globulins. Blood 1972; 39: 210-223.
    • (1972) Blood , vol.39 , pp. 210-223
    • Coleman, M.1    Vigliano, E.M.2    Weksler, M.E.3
  • 68
    • 0017797398 scopus 로고
    • Platelet functions in dysproteinaemia
    • Kasturi J, Saraya AK. Platelet functions in dysproteinaemia. Acta Haematol 1978; 59: 104-113.
    • (1978) Acta Haematol , vol.59 , pp. 104-113
    • Kasturi, J.1    Saraya, A.K.2
  • 69
    • 18844374852 scopus 로고    scopus 로고
    • Characterization of a myeloma patient with a life-threatening hemorrhagic diathesis: Presence of a lambda dimer protein inhibiting shear-induced platelet aggregation by binding to the A1 domain of von Willebrand factor
    • Shinagawa A, Kojima H, Berndt MC, et al. Characterization of a myeloma patient with a life-threatening hemorrhagic diathesis: presence of a lambda dimer protein inhibiting shear-induced platelet aggregation by binding to the A1 domain of von Willebrand factor. Thromb Haemost 2005; 93: 889-896.
    • (2005) Thromb Haemost , vol.93 , pp. 889-896
    • Shinagawa, A.1    Kojima, H.2    Berndt, M.C.3
  • 71
    • 0022615123 scopus 로고
    • A myeloma paraprotein with specificity for platelet glycoprotein IIIa in a patient with a fatal bleeding disorder
    • DiMinno G, Coraggio F, Cerbone AM, et al. A myeloma paraprotein with specificity for platelet glycoprotein IIIa in a patient with a fatal bleeding disorder. J Clin Invest 1986; 77: 157-164.
    • (1986) J Clin Invest , vol.77 , pp. 157-164
    • DiMinno, G.1    Coraggio, F.2    Cerbone, A.M.3
  • 72
    • 33645074412 scopus 로고    scopus 로고
    • Aspirin use in myeloma: A note of caution regarding potential tumour necrosis factor-alpha elevation
    • Kast RE. Aspirin use in myeloma: a note of caution regarding potential tumour necrosis factor-alpha elevation. Br J Haematol 2006; 133: 216.
    • (2006) Br J Haematol , vol.133 , pp. 216
    • Kast, R.E.1
  • 73
    • 33746593667 scopus 로고    scopus 로고
    • Enoxaparin or aspirin for the prevention of recurrent thromboembolism in newly diagnosed myeloma patients treated with melphalan and prednisone plus thalidomide or lenalidomide
    • Palumbo A, Rus C, Zeldis JB, et al. Enoxaparin or aspirin for the prevention of recurrent thromboembolism in newly diagnosed myeloma patients treated with melphalan and prednisone plus thalidomide or lenalidomide. J Thromb Haemost 2006; 4: 1842-1845.
    • (2006) J Thromb Haemost , vol.4 , pp. 1842-1845
    • Palumbo, A.1    Rus, C.2    Zeldis, J.B.3
  • 74
    • 33745590139 scopus 로고    scopus 로고
    • Thrombotic complications in patients with newly diagnosed multiple myeloma treated with lenalidomide and dexamethasone: Benefit of aspirin prophylaxis
    • author reply 404
    • Zonder JA, Barlogie B, Durie BG, et al. Thrombotic complications in patients with newly diagnosed multiple myeloma treated with lenalidomide and dexamethasone: benefit of aspirin prophylaxis. Blood 2006; 108: 403; author reply 404.
    • (2006) Blood , vol.108 , pp. 403
    • Zonder, J.A.1    Barlogie, B.2    Durie, B.G.3
  • 75
    • 33644823017 scopus 로고    scopus 로고
    • Doxorubicin and dexamethasone followed by thalidomide and dexamethasone is an effective well tolerated initial therapy for multiple myeloma
    • Hassoun H, Reich L, Klimek VM, et al. Doxorubicin and dexamethasone followed by thalidomide and dexamethasone is an effective well tolerated initial therapy for multiple myeloma. Br J Haematol 2006; 132: 155-161.
    • (2006) Br J Haematol , vol.132 , pp. 155-161
    • Hassoun, H.1    Reich, L.2    Klimek, V.M.3
  • 76
    • 28544451098 scopus 로고    scopus 로고
    • Thalidomide therapy and deep venous thrombosis in multiple myeloma
    • Rajkumar SV. Thalidomide therapy and deep venous thrombosis in multiple myeloma. Mayo Clin Proc 2005; 80: 1549-1551.
    • (2005) Mayo Clin Proc , vol.80 , pp. 1549-1551
    • Rajkumar, S.V.1
  • 77
    • 28544436819 scopus 로고    scopus 로고
    • The role of aspirin in the prevention of thrombotic complications of thalidomide and anthracycline-based chemotherapy for multiple myeloma
    • Baz R, Li L, Kottke-Marchant K, et al. The role of aspirin in the prevention of thrombotic complications of thalidomide and anthracycline-based chemotherapy for multiple myeloma. Mayo Clin Proc 2005; 80: 1568-1574.
    • (2005) Mayo Clin Proc , vol.80 , pp. 1568-1574
    • Baz, R.1    Li, L.2    Kottke-Marchant, K.3
  • 78
    • 3242760702 scopus 로고    scopus 로고
    • First-line therapy with thalidomide and dexamethasone in preparation for autologous stem cell transplantation for multiple myeloma
    • Cavo M, Zamagni E, Tosi P, et al. First-line therapy with thalidomide and dexamethasone in preparation for autologous stem cell transplantation for multiple myeloma. Haematologica 2004; 89: 826-831.
    • (2004) Haematologica , vol.89 , pp. 826-831
    • Cavo, M.1    Zamagni, E.2    Tosi, P.3
  • 79
    • 33745605185 scopus 로고    scopus 로고
    • Does low-dose aspirin have antineoplastic effects in multiple myeloma?
    • Baz R, Hussein MA. Does low-dose aspirin have antineoplastic effects in multiple myeloma? Br J Haematol 2006; 134: 349-350.
    • (2006) Br J Haematol , vol.134 , pp. 349-350
    • Baz, R.1    Hussein, M.A.2
  • 81
    • 33749838965 scopus 로고    scopus 로고
    • Anticoagulation regimens for thalidomide and lenalidomide
    • Zangari M. Anticoagulation regimens for thalidomide and lenalidomide. Clin Adv Hematol Oncol 2006; 4: 658-659.
    • (2006) Clin Adv Hematol Oncol , vol.4 , pp. 658-659
    • Zangari, M.1
  • 83
    • 36849070772 scopus 로고    scopus 로고
    • American Society of Clinical Oncology guideline: Recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer
    • Lyman GH, Khorana AA, Falanga A, et al. American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol 2007; 25: 5490-5505.
    • (2007) J Clin Oncol , vol.25 , pp. 5490-5505
    • Lyman, G.H.1    Khorana, A.A.2    Falanga, A.3
  • 84
    • 25144496456 scopus 로고    scopus 로고
    • Low-molecular-weight heparin and survival in patients with malignant disease
    • Kakkar AK. Low-molecular-weight heparin and survival in patients with malignant disease. Cancer Control 2005; 12 (Suppl 1): 22-30.
    • (2005) Cancer Control , vol.12 , Issue.SUPPL. 1 , pp. 22-30
    • Kakkar, A.K.1


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.